Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748095 | 0.88 | KMT2A (0.78) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL8129225 | 0.83 | CYP3A4 (0.84) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL8261943 | 0.82 | KMT2A (0.69) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL19783432 | 0.82 | KMT2A (0.69) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL8358173 | 0.82 | LMNA (0.71) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL144993 | 0.81 | KMT2A (0.69) | KMT2AALDH1A1CYP3A4TSHRMAPT | |
| SCHEMBL19782882 | 0.81 | KMT2A (0.68) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL21459844 | 0.81 | KMT2A (0.68) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL21460004 | 0.81 | KMT2A (0.68) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL19776493 | 0.81 | KMT2A (0.68) | KMT2ATP53ALDH1A1HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120423-B | Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same | 柳韩洋行 | 2026-02-27 | — | — | CN | disclosed |
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-05-30 | — | — | US | disclosed |
| EP-4313965-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120423-A | Novel indoleamine 2,3-dioxygenase inhibitors, process for preparing the same and pharmaceutical compositions containing the same | 柳韩洋行 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022203332-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-09-29 | — | — | WO | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2892525-B1 | METHODS OF TREATING MUSCULAR DYSTROPHY | UNIV NEVADA RENO (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| EP-0030632-B1 | BENZOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | MERCK PATENT GmbH (DE) | 1985-02-20 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| US-4465504-A | Herbicidally active novel N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic acid amides and intermediates therefor | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4455428-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-19 | — | — | US | disclosed |
| EP-0029171-B1 | AZOLYLOXY-CARBOXYLIC ACID N-OXY-AMIDES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, THEIR USE, HERBICIDES CONTAINING THEM AND THEIR PREPARATION | BAYER AG (DE) | 1984-03-21 | — | — | EP | disclosed |
| US-4408055-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| EP-0081730-A1 | Process for the preparation of hetaryloxyacetamides | BAYER AG (DE) | 1983-06-22 | — | — | EP | disclosed |
| EP-0060426-A2 | N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic-acid amides, their preparation and use as herbicides and intermediates for their preparation | BAYER AG (DE) | 1982-09-22 | — | — | EP | disclosed |
| US-4294839-A | Benzothiazole derivatives and pharmaceutical formulations containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-10-13 | — | — | US | disclosed |
| EP-0030632-A2 | Benzothiazole derivatives, pharmaceutical compositions containing them and process for their preparation | MERCK PATENT GmbH (DE) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885TP53 4875/4885ALDH1A1 342/4885 |
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDO1, IDO2, INMT | KMT2A 296/4885TP53 3193/4885ALDH1A1 1514/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | KMT2A 3360/4885TP53 4875/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.